New hope for kids: drug trial aims to shield transplant patients from dangerous viruses
NCT ID NCT07488728
Summary
This study is testing if a drug called letermovir can prevent serious viral infections in children after they receive a stem cell transplant for certain severe, EBV-related blood diseases. It will involve 80 children under 18 who are at high risk for these infections. The main goal is to see if the drug reduces infections from viruses like CMV and EBV, and if it helps with other transplant complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-ASSOCIATED T/NK-CELL LYMPHOPROLIFERATIVE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Children's Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.